公开(公告)号：US20230295265A1

公开(公告)日：2023-09-21

申请号：US18156887

申请日：2023-01-19

Applicant: The Regents of The University of Colorado, A Body Corporate

Inventor： Brian Freed ,  Christina Roark ,  Elizabeth Sunderhaus

IPC: C07K14/74 ,  A61K35/17 ,  A61K35/28 ,  A61P37/06 ,  C12Q1/6881

CPC classification number: C07K14/70539 ,  A61K35/17 ,  A61K35/28 ,  A61P37/06 ,  C12Q1/6881

Abstract: Methods of preventing or treating autoimmune disease are disclosed. In some cases, subjects with having or at risk of developing autoimmune disease are identified as possessing one or more autoimmunity-susceptibility HLA alleles at one or more HLA loci. In many cases, the HLA loci are selected from Class I and Class II loci, for example Class I A, B, and C, and Class II DQ, DR, and DP. In many cases, subjects suffering from or at risk of developing an autoimmune disease may be administered a plurality engineered autologous HSCs modified to carry and express a variant susceptibility allele having at least one mutation in the antigen binding cleft that alters antigen binding and/or specificity of that variant HLA molecule. In many embodiments, the engineered HSCs are CD34+ immune cells that express one or more modified HLA proteins.

公开(公告)号：US20230159617A1

公开(公告)日：2023-05-25

申请号：US17861954

申请日：2022-07-11

Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

Inventor： Brian Freed ,  Christina Roark ,  Elizabeth Sunderhaus

IPC: C07K14/74

CPC classification number: C07K14/70539

Abstract: Methods of preventing or treating autoimmune disease are disclosed. In some cases, subjects with having or at risk of developing autoimmune disease are identified as possessing one or more autoimmunity-susceptibility HLA alleles at one or more HLA loci. In many cases, the HLA loci are selected from Class I and Class II loci, for example Class I A, B, and C, and Class II DQ, DR, and DP. In many cases, subjects suffering from or at risk of developing an autoimmune disease may be administered a plurality engineered autologous HSCs modified to carry and express a variant susceptibility allele having at least one mutation in the antigen binding cleft that alters antigen binding and/or specificity of that variant HLA molecule. In many embodiments, the engineered HSCs are CD34+ immune cells that express one or more modified HLA proteins.

公开(公告)号：US20230192808A1

公开(公告)日：2023-06-22

申请号：US17741438

申请日：2022-05-10

Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

Inventor： Brian Freed ,  Christina Roark ,  Elizabeth Sunderhaus

IPC: C07K14/74 ,  A61K35/17 ,  A61P37/06 ,  A61K35/28 ,  C12Q1/6881

CPC classification number: C07K14/70539 ,  A61K35/17 ,  A61P37/06 ,  A61K35/28 ,  C12Q1/6881

Abstract: Methods of preventing or treating autoimmune disease are disclosed. In some cases, subjects with having or at risk of developing autoimmune disease are identified as possessing one or more autoimmunity-susceptibility HLA alleles at one or more HLA loci. In many cases, the HLA loci are selected from Class I and Class II loci, for example Class I A, B, and C, and Class II DQ, DR, and DP. In many cases, subjects suffering from or at risk of developing an autoimmune disease may be administered a plurality engineered autologous HSCs modified to carry and express a variant susceptibility allele having at least one mutation in the antigen binding cleft that alters antigen binding and/or specificity of that variant HLA molecule. In many embodiments, the engineered HSCs are CD34+ immune cells that express one or more modified HLA proteins.

公开(公告)号：US20230123094A1

公开(公告)日：2023-04-20

申请号：US17861914

申请日：2022-07-11

Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

Inventor： Brian Freed ,  Christina Roark ,  Elizabeth Sunderhaus

IPC: C12N5/0775 ,  C12N15/86 ,  C07K14/74

Abstract: Methods of preventing or treating autoimmune disease are disclosed. In some cases, subjects with having or at risk of developing autoimmune disease are identified as possessing one or more autoimmunity-susceptibility HLA alleles at one or more HLA loci. In many cases, the HLA loci are selected from Class I and Class II loci, for example Class I A, B, and C, and Class II DQ, DR, and DP. In many cases, subjects suffering from or at risk of developing an autoimmune disease may be administered a plurality engineered autologous HSCs modified to carry and express a variant susceptibility allele having at least one mutation in the antigen binding cleft that alters antigen binding and/or specificity of that variant HLA molecule. In many embodiments, the engineered HSCs are CD34+ immune cells that express one or more modified HLA proteins.

公开(公告)号：US20230126183A1

公开(公告)日：2023-04-27

申请号：US17861943

申请日：2022-07-11

Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

Inventor： Brian Freed ,  Christina Roark ,  Elizabeth Sunderhaus

IPC: C07K14/74 ,  A61P37/02

Abstract: Methods of preventing or treating autoimmune disease are disclosed. In some cases, subjects with having or at risk of developing autoimmune disease are identified as possessing one or more autoimmunity-susceptibility HLA alleles at one or more HLA loci. In many cases, the HLA loci are selected from Class I and Class II loci, for example Class I A, B, and C, and Class II DQ, DR, and DP. In many cases, subjects suffering from or at risk of developing an autoimmune disease may be administered a plurality engineered autologous HSCs modified to carry and express a variant susceptibility allele having at least one mutation in the antigen binding cleft that alters antigen binding and/or specificity of that variant HLA molecule. In many embodiments, the engineered HSCs are CD34+ immune cells that express one or more modified HLA proteins.

公开(公告)号：US20230091257A1

公开(公告)日：2023-03-23

申请号：US17744554

申请日：2022-05-13

Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

Inventor： Brian Freed ,  Christina Roark ,  Elizabeth Sunderhaus

IPC: C07K14/74 ,  C12N15/62 ,  C12N15/86 ,  A61K35/17 ,  A61P37/06

Abstract: Methods of preventing or treating autoimmune disease are disclosed. In some cases, subjects with having or at risk of developing autoimmune disease are identified as possessing one or more autoimmunity-susceptibility HLA alleles at one or more HLA loci. In many cases, the HLA loci are selected from Class I and Class II loci, for example Class I A, B, and C, and Class II DQ, DR, and DP. In many cases, subjects suffering from or at risk of developing an autoimmune disease may be administered a plurality engineered autologous HSCs modified to carry and express a variant susceptibility allele having at least one mutation in the antigen binding cleft that alters antigen binding and/or specificity of that variant HLA molecule. In many embodiments, the engineered HSCs are CD34+ immune cells that express one or more modified HLA proteins.